Algernon Posts Mixed Bag Results From Mid Stage Chronic Cough Study
Algernon Pharmaceuticals Inc (OTC:AGNPF) has announced topline data showing that it has met the co-primary endpoint in its Phase 2 proof…
PMV Pharma, Merck Ink Clinical Trial Collaboration For Combination Study In Solid Tumors
PMV Pharmaceuticals Inc (NASDAQ:PMVP) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE:MRK) to evaluate PC14586…
Apyx Medical’s Renuvion Scores FDA Approval To Eliminate Sagging Neck
The FDA has granted 510(k) clearance for Apyx Medical Corporation’s (NASDAQ:APYX) Renuvion for subcutaneous dermatological and aesthetic procedures to improve the appearance…
Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO
Following its End of Phase 2 Meeting with the FDA, Entera Bio Ltd (NASDAQ:ENTX) has designed the pivotal study for EB613 as…
Medigus’ Polyrizon Inks Agreement To Develop Therapies For Traumatic Spinal Cord Injuries
Polyrizon Ltd, in which Medigus Ltd (NASDAQ:MDGS) owns a 37.03% stake, signed a binding Collaboration Agreement with NurExone Biologic Inc for therapies for traumatic spinal…
GSK Completes Spin Off Of Its Consumer Healthcare Business
GSK plc (NYSE:GSK) has completed the demerger of the Consumer Healthcare business to form the Haleon Group. Reuters reported that shares in…
SVB Leerink Sees ‘Cheaper Way’ To Pharma Digital Marketing With This Stock
SVB Leerink initiated coverage on OptimizeRx Corporation (NASDAQ:OPRX) with a buy rating and a price target of $38, implying an upside of…
HC Wainwright Rating & Price Target On TherapeuticsMD Under Review On ‘Unclear Path’
The merger agreement between EW Partners and TherapeuticsMD Inc (NASDAQ:TXMD) was terminated, with EW Partners not acquiring the majority of shares…
HC Wainwright Reiterates On Pluristem After Encouraging Initial Data
Yesterday Pluristem Therapeutics Inc (NASDAQ: PSTI) announced top-line results from its Phase 3 trial evaluating PLX-PAD in 240 patients for muscle recovery following hip fracture surgery.
Alnylam Hits Moderna With Another Patent Infringement Suit-Related To COVID-19 Vaccine
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) added one more patent infringement lawsuit against Moderna Inc (NASDAQ:MRNA), claiming it violated a newly obtained patent. The…